These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 34641391)

  • 1. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
    Tong JTW; Harris PWR; Brimble MA; Kavianinia I
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepping forward in antibody-drug conjugate development.
    Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
    Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
    Chia CSB
    ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
    Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
    Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
    Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
    Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
    Fu Z; Li S; Han S; Shi C; Zhang Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
    Pramanik D
    Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
    Takakura T; Shimizu T; Yamamoto N
    Jpn J Clin Oncol; 2024 Aug; 54(8):837-846. PubMed ID: 38704241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preface for special issue: "Emerging strategies, technologies, and approaches for the next generation ADCs".
    Walles M; Xu K
    Xenobiotica; 2024 Aug; 54(8):439-441. PubMed ID: 39073838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug conjugate-based anticancer therapy - Current status and perspectives.
    Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
    Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
    Sau S; Alsaab HO; Kashaw SK; Tatiparti K; Iyer AK
    Drug Discov Today; 2017 Oct; 22(10):1547-1556. PubMed ID: 28627385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.